Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Österreich)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
ABBVIE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 174.1 USD | -0.41% |
|
+3.21% | +12.33% |
| Feb. 09 | ETF of the week: Dividend lovers are in luck |  |
| Feb. 08 | AbbVie's VYALEV?? (foslevodopa/Foscarbidopa Solution) Available for the Treatment of Advanced Parkinson's Disease in Canada | CI |
Financials (USD)
| Sales 2023 | 54.32B | Sales 2024 * | 54.42B | Capitalization | 307B |
|---|---|---|---|---|---|
| Net income 2023 | 4.86B | Net income 2024 * | 9.57B | EV / Sales 2023 | 5.04 x |
| Net Debt 2023 * | 45.68B | Net Debt 2024 * | 46.42B | EV / Sales 2024 * | 6.5 x |
| P/E ratio 2023 |
57
x | P/E ratio 2024 * |
31.3
x | Employees | 50,000 |
| Yield 2023 * |
3.42% | Yield 2024 * |
3.56% | Free-Float | 96.74% |
More Fundamentals
* Assessed data
More news
Latest transcript on AbbVie Inc.
More recommendations
More press releases
More news
| 1 day | -0.41% | ||
| 1 week | +3.21% | ||
| Current month | +5.89% | ||
| 1 month | +5.57% | ||
| 3 months | +25.61% | ||
| 6 months | +14.95% | ||
| Current year | +12.33% |
1 week
168.45
175.91
1 month
161.00175.91
Current year
154.77175.91
1 year
130.96175.91
3 years
102.05175.91
5 years
62.55175.91
10 years
45.45175.91
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 12-12-31 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 12-12-31 |
Robert Michael
PSD | President | 53 | 11-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 12-12-31 |
Edward Rapp
BRD | Director/Board Member | 66 | 12-12-31 |
| Director/Board Member | 70 | 12-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.12% | 6 M€ | +0.93% | - | |
| 6.85% | 19 M€ | +2.97% | - | |
| 6.26% | 13 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-02-09 | 174.1 | -0.41% | 3,502,661 |
| 24-02-08 | 174.8 | -0.13% | 5,709,326 |
| 24-02-07 | 175 | +0.99% | 6,409,084 |
| 24-02-06 | 173.3 | +1.19% | 7,038,000 |
| 24-02-05 | 171.3 | +1.54% | 6,486,886 |
Delayed Quote Nyse, February 09, 2024 at 04:00 pm EST
More quotes
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (78.7%), Germany (2.3%), Canada (2%), Japan (1.6%), China (1.6%), France (1.4%), Australia (0.9%), Spain (0.9%), the United Kingdom (0.8%), Italy (0.8%), Brazil (0.7%) and other (8.3%).
Sector
Pharmaceuticals
Calendar
2024-04-24
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
174.1
USD
Average target price
178.4
USD
Spread / Average Target
+2.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.33% | 307 B $ | |
| +26.97% | 666 B $ | |
| +19.17% | 536 B $ | |
| +0.01% | 377 B $ | |
| +15.07% | 318 B $ | |
| -8.02% | 207 B $ | |
| +4.05% | 206 B $ | |
| -7.92% | 191 B $ | |
| -4.27% | 156 B $ | |
| -3.63% | 117 B $ |
